
THE UNIVERSITY OF GREIFSWALD AND ESOCAP SIGN LICENSING DEAL FOR A SMART APPLICATION TECHNOLOGY IN THE UPPER GASTROINTESTINAL TRACT



Basel, Switzerland, July 28th, 2017

EsoCap AG and the University of Greifswald in Germany announced that they have entered into a licensing agreement granting EsoCap the exclusive worldwide rights for the unique drug delivery technology developed by the University of Greifswald.

Prof. Werner Weitschies, Head of the Center of Drug Absorption and Transport and his team at the University of Greifswald showed that the local therapy of diseases of the upper gastrointestinal tract is now feasible with this smart application technology.

“This is a highly exciting time in the field of drug delivery” Weitschies said. “Up to now the specific site-directed treatment of esophagitis was not possible due to the ultra-short transit time in the esophagus. Our work revealed the potent role of our technology enabling local treatment in esophagitis. Our relationship with EsoCap will allow to rapidly bring our unique drug delivery technology into clinical testing in patients.”

“This exclusive worldwide license grants EsoCap a leading position in the development of drug delivery applications in the upper gastrointestinal tract” said Dr. Werner Tschollar, Chairman of the Board of EsoCap. “We are committed to working closely with the University of Greifswald on this technology to rapidly develop therapies to help patients suffering of diseases of the upper gastrointestinal tract worldwide. This technology may be beneficial in at least 6 indications affecting 370 Mio patients.”

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

About the University of Greifswald

Across numerous departments and disciplines, the University of Greifswald community advances ideas and innovations that enrich human life. The University’s departments encompass a wide range of fields, including General and Clinical Pharmacology, Biopharmaceutics and Pharmaceutical Technology, Pharmaceutical Biotechnology all clinical disciplines. The Center of Drug Absorption and Transport (C_DAT) is an internationally recognized center of expertise in which research groups of the University of Greifswald and the University Medical Center Greifswald investigate the processes of absorption and transport of drugs through to their desired - and unwanted - sites of effect in the human body.



EsoCap

Contacts:

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com

University of Greifswald
Center of Drug Absorption and Transport
Institute of Pharmacy
Felix-Hausdorff-Strasse 3
17487 Greifswald
Germany

werner.weitschies@uni-greifswald.de